Viking Therapeutics, Inc. has emerged as a strong contender in the expanding market for oral GLP-1 obesity drugs, following impressive Phase 2 trial results for its...
BioNTech SE experienced an approximately 8% increase in its shares during premarket trading on Friday following the announcement of positive results from a Phase 3 clinical...
